UY35329A - Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma. - Google Patents

Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.

Info

Publication number
UY35329A
UY35329A UY0001035329A UY35329A UY35329A UY 35329 A UY35329 A UY 35329A UY 0001035329 A UY0001035329 A UY 0001035329A UY 35329 A UY35329 A UY 35329A UY 35329 A UY35329 A UY 35329A
Authority
UY
Uruguay
Prior art keywords
oral administration
prepare
pharmaceutical composition
same
fexofenadine
Prior art date
Application number
UY0001035329A
Other languages
English (en)
Inventor
Georges Daste
Benjamin Derouet
Marie Renouard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY35329A publication Critical patent/UY35329A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para administración oral, comprendiendo dichas composiciones pectina de alto contenido en metoxi, glicerol, agua y fexofenadina, o una sal de la misma farmacéuticamente aceptable. La invención también se refiere a los usos de estas co mposiciones como un medicamento y al proceso para preparar dichas composiciones.
UY0001035329A 2013-02-14 2014-02-14 Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma. UY35329A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305173 2013-02-14

Publications (1)

Publication Number Publication Date
UY35329A true UY35329A (es) 2014-09-30

Family

ID=47739181

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035329A UY35329A (es) 2013-02-14 2014-02-14 Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.

Country Status (4)

Country Link
AR (1) AR094761A1 (es)
TW (1) TW201440808A (es)
UY (1) UY35329A (es)
WO (1) WO2014125052A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587106A (zh) * 2018-01-15 2020-08-25 西雅图咖米公司 半固态抗组胺组合物及其制备和使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物
KR101303479B1 (ko) * 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제

Also Published As

Publication number Publication date
AR094761A1 (es) 2015-08-26
TW201440808A (zh) 2014-11-01
WO2014125052A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
NZ709958A (en) Enhanced stability of novel liquid compositions
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
BR112016012489A2 (pt) cápsula, método de preparação de uma cápsula contendo flavonoides totais de desmodium styracifolium, e uso da cápsula
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201600394A1 (ru) Трициклические соединения пиперидина
BR112016005361A8 (pt) inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos
UY35235A (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
UY35329A (es) Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab
IN2013CH04314A (es)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211105